Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | APEX1 | P27695 | 7/20 | 0.56 |
| ▸ | MYC | P01106 | 10/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13735857 | 0.91 | POLB (0.58) | POLBMAPTTDP1L3MBTL1APEX1 | |
| SCHEMBL13833660 | 0.88 | MAPT (0.66) | POLBMAPTTDP1L3MBTL1APEX1 | |
| SCHEMBL13833777 | 0.80 | MAPT (0.58) | POLBMAPTTDP1L3MBTL1APEX1 | |
| SCHEMBL14777503 | 0.79 | POLB (0.55) | POLBMAPTTDP1L3MBTL1APEX1 | |
| SCHEMBL13833837 | 0.79 | POLB (0.64) | POLBMAPTTDP1L3MBTL1APEX1 | |
| SCHEMBL13833651 | 0.75 | POLB (0.53) | POLBMAPTTDP1L3MBTL1APEX1 | |
| SCHEMBL13833836 | 0.75 | POLB (0.53) | POLBMAPTTDP1L3MBTL1APEX1 | |
| SCHEMBL13833663 | 0.73 | APEX1 (0.74) | POLBMAPTTDP1L3MBTL1APEX1 | |
| SCHEMBL18295789 | 0.73 | MYC (0.74) | APEX1MYC | |
| SCHEMBL13833709 | 0.72 | KDM4E (0.55) | POLBMAPTTDP1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2012154888-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | HSPA5, PSMG3, VCP | POLB 2314/4885MAPT 221/4885TDP1 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.